<h3>Objective(s)</h3> The purpose of this systematic review was to examine the current literature on the integration of pharmacological interventions within neurorehabilitation and neuropsychological testing settings in patients with Traumatic Brain Injury (TBI). <h3>Data Sources</h3> This review was conducted using the following databases: Taylor & Francis, Science Direct, Google Scholar, and ProQuest Central. Inclusion criteria consisted of peer-reviewed articles published in English between the years of 2006-2020. Keywords for the search included pharmacotherapy, beta-blockers, adrenergic antagonists, neurorehabilitation, neuropsychological testing, and traumatic brain injury (TBI). <h3>Study Selection</h3> Literature Review. <h3>Data Extraction</h3> Independent extraction by multiple observers. <h3>Data Synthesis</h3> In cases of TBI or other insults to the cerebral cortex, patients may experience a wide array of cognitive & somatic anxiety symptomatology. The literature reviewed shows that adrenergic antagonist agents may help get patients up to a baseline performance level to obtain more accurate psychometric measurements. <h3>Conclusions</h3> When not contraindicated, beta-blockers (e.g., propranolol) have the potential to be incorporated safely on an as-needed basis for patients undergoing neurorehabilitation and neuropsychological testing within an interdisciplinary, integrated healthcare environment. Studies show beta-blockers can lessen cognitive anxiety via a decrease in somatization, in turn yielding more accurate results of cognitive ability, deficits, or improvement. Contrary to anxiolytic sedative-hypnotic agents (e.g., benzodiazepines), which have risks of cognitive impairments, data shows that beta-blockers may be an appropriate choice in neurorehabilitative interventions and neuropsychological testing because their intake does not result in an artificially enhanced cognitive ability. <h3>Author(s) Disclosures</h3> N/A.